
Brill Research
19.5K posts

Brill Research
@BrillResearch
Investment theses backed by deep fundamental & technical analysis




$BNTX is, in my opinion, significantly undervalued. - 20+ ongoing Phase II & III studies - A COVID business still generating a ~$2B annual revenue run rate - Over $18B in cash and equivalents

$BNTX sitting on ~$19.7B in cash (current FX) with promising clinical progress for pumitamig. Still a waiting game until oncology launches materialize. A $1 billion SRP feels premature — better to deploy that capital into BD or keep it in yield-generating securities to fund R&D.

$APPS is shooting out of the gate again today, looking ready to break through the $10 area. There are still over 10M shares sold short, with weekly and monthly charts curling higher on strong volume. I remain long.

$AMD is positioned to become a giant and today´s share price will seem like peanuts in 5yrs🧵


$APPS has seen multiple spikes toward the $10 level over the past year, but this move feels different. The stock surged following solid earnings, and historically, similar rallies were sold off heavily in the following weeks. This time, however, it is holding up remarkably well.



$APPS continues to rally, now approaching $10/share. As mentioned previously, the latest earnings report showed encouraging progress and a clear path toward continued revenue growth, profitability expansion, and debt reduction.

$APPS showing a major weekly breakout here and curling up very nicely on extraordinary volume following quarterly results. The company returned to double-digit revenue and EBITDA growth while also deleveraging with a $50M debt paydown.



